A key step towards reducing the burden of central nervous system (CNS) disorders is the identification of disease-specific biomarkers that can help predict, monitor, and guide treatment development.

The central nervous system (CNS) critically depends on the integrity of oligodendrocytes, specialised glial cells responsible for the formation and maintenance of myelin sheaths. Myelin not only ...

Guanosine, a purine nucleoside, has emerged as a potent modulator within the central nervous system (CNS), contributing to neuroprotection through a diverse array of mechanisms. It plays a critical ...

Learning how cells in the brain regulate their response to injury and disease is informing the understanding of neurological disorders and uncovering new paths for treatment. Findings from a new study ...

Researchers at Lund University in Sweden have created a method that makes it possible to transform the brain's support cells into parvalbumin-positive cells. These cells act as the brain's ...

WEST LAFAYETTE, Ind. – Purdue University researchers have created an electronic chip that may provide improved support for the hundreds of millions of people worldwide the World Health Organization ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Each part of the nervous system uses internal checks and balances to regulate its activity, responding to various factors like mood, health status, and the external environment.¹ These regulatory ...

Neuroscience companies have raised more money from VCs in recent years, thanks to new research. In 2021, private biotech firms targeting neurological diseases raised $2.61 billion from investors. Here ...